Charles F. Wagner, Jr

2020

In 2020, Charles F. Wagner, Jr earned a total compensation of $6.1M as EVP & Chief Financial Officer at Vertex Pharmaceuticals, a 75% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$946,680
Salary$726,923
Stock Awards$4,375,585
Other$41,202
Total$6,090,390

Wagner received $4.4M in stock awards, accounting for 72% of the total pay in 2020.

Wagner also received $946.7K in non-equity incentive plan, $726.9K in salary and $41.2K in other compensation.

Rankings

In 2020, Charles F. Wagner, Jr's compensation ranked 1,707th out of 13,090 executives tracked by ExecPay. In other words, Wagner earned more than 87.0% of executives.

ClassificationRankingPercentile
All
1,707
out of 13,090
87th
Division
Manufacturing
648
out of 5,621
89th
Major group
Chemicals And Allied Products
232
out of 2,254
90th
Industry group
Drugs
195
out of 1,954
90th
Industry
Pharmaceutical Preparations
136
out of 1,459
91st
Source: SEC filing on April 7, 2022.

Wagner's colleagues

We found three more compensation records of executives who worked with Charles F. Wagner, Jr at Vertex Pharmaceuticals in 2020.

2020

Jeffrey Leiden

Vertex Pharmaceuticals

Chairman

2020

Reshma Kewalramani

Vertex Pharmaceuticals

Chief Executive Officer

2020

Stuart Arbuckle

Vertex Pharmaceuticals

Chief Operating Officer

News

You may also like